E!9524,ASCEND,Karolinka Institutet
| Reference number | |
| Coordinator | Karolinska Institutet |
| Funding from Vinnova | SEK 1 999 913 |
| Project duration | April 2026 - March 2028 |
| Status | Ongoing |
| Venture | Eurostars |
Purpose and goal
This project aims to develop MY012, a monoclonal antibody targeting ASC, a key component of the inflammasome pathway, for the treatment of inflammatory bowel diseases (IBD). My laboratory will contribute expertise in human organoid–based disease models and transcriptomic analysis to better understand patient heterogeneity and improve the ability to predict responses to MY012 and future therapies.
Expected effects and result
The final product will be a novel monoclonal anti-inflammasome antibody targeting the ASC protein, designated MY012. The pharmacological activity of MY012 is expected to be concentrated at sites of pathological ASC speck propagation resulting from chronic inflammation, such as the intestinal mucosa of patients with IBD.
Planned approach and implementation
The project will build on existing data showing the therapeutic potential of targeting ASC with MY012 in two preclinical systems: a mouse model of acute inflammation and ex vivo intestinal organoids. In parallel, the team will perform transcriptomic analyses to identify novel IBD biomarkers and molecular signatures to support patient stratification and improve understanding of IBD pathophysiology.